10-Q: Lantheus Holdings Q1 2026 Earnings Show Revenue Growth

Lantheus Holdings reported a 1.2% increase in revenue for the first quarter of 2026, driven by strong performance in Neuraceq and DEFINITY, despite a decrease in PYLARIFY sales.

Summary

• Lantheus Holdings reported total revenues of $377.3 million for the three months ended March 31, 2026, a 1.2% increase compared to $372.8 million in the same period of 2025.
• Gross profit decreased by 2.9% to $230.9 million, primarily due to higher cost of goods sold and increased operating expenses.
• Operating income saw a significant decrease of 20.3% to $81.3 million, impacted by higher sales and marketing, and R&D expenses.
• Net income increased by 62.3% to $118.4 million, largely due to a $59.3 million gain on the sale of the SPECT business.
• The company completed the sale of its SPECT business on January 1, 2026, recognizing a substantial gain.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with solid operational performance offset by increased expenses and a significant one-time gain from a divestiture.

Positives

• Total revenues increased by 1.2% to $377.3 million in Q1 2026.
• Neuraceq revenue saw a 100% increase, driven by the acquisition of Lantheus Biosciences.
• DEFINITY revenue increased by 6.8% to $84.6 million.
• Strategic partnerships and other revenue grew by 52.1% to $16.3 million.
• A gain of $59.3 million was recognized from the sale of the SPECT business.
• Cash flow from operating activities increased to $125.1 million from $107.6 million in the prior year period.

Negatives

• Gross profit decreased by 2.9% to $230.9 million.
• Operating income decreased by 20.3% to $81.3 million.
• Sales and marketing expenses increased by 24.0% to $52.7 million.
• Research and development expenses increased by 8.4% to $39.4 million.
• PYLARIFY revenue decreased by 6.5% to $240.9 million, impacted by a lower net sales price.
• The SPECT business revenue, which was $25.2 million in Q1 2025, is no longer present in Q1 2026.

Risks

• The company may not realize expected benefits from PYLARIFY TruVu, including challenges in technology transfer, FDA approval for manufacturing sites, and obtaining adequate reimbursement.
• There is no assurance that customers will transition from PYLARIFY to PYLARIFY TruVu as planned, potentially leading to loss of customers to competitors.
• The company may not realize expected benefits from the acquisition of rights to LNTH-2501, including potential delays in FDA approval, market acceptance, and manufacturing scale-up.
• The company may not realize expected benefits from the POINT Biopharma Global Inc. license agreements, including PNT2003, due to challenges in development, manufacturing, regulatory approval, and potential disagreements with POINT.
• The company may not receive the expected financial benefits from the sale of its SPECT business, as future and contingent payments are subject to the financial resources of SHINE SPECT and achievement of revenue milestones.
• Competition for PSMA PET imaging agents is increasing, with potential for generic entrants and alternative tracers.
• Reimbursement dynamics for diagnostic radiopharmaceuticals, particularly the shift from Transitional Pass-Through (TPT) Status to Mean Unit Cost (MUC) for PYLARIFY, could affect customer purchasing decisions.
• The company is dependent on third parties for the manufacturing of certain products, which could lead to delays or supply disruptions.

Future Outlook

The company anticipates continued market expansion for its established products, PYLARIFY, DEFINITY, and Neuraceq, and is focused on the successful commercialization of PYLARIFY TruVu, LNTH-2501, and PNT2003. Future growth is expected to be driven by strategic acquisitions, pipeline development, and expansion into new markets. The company is also streamlining operations to focus on its radiodiagnostic business and explore value-maximizing alternatives for its radiotherapeutic assets.

Management Comments

• The company announced an updated strategic focus on innovative PET radiodiagnostics, informed by its capabilities and customer relationships.
• The company has taken purposeful, disciplined actions to optimize its portfolio and strengthen its commercial and development capabilities.
• The company plans to work closely with clinicians and PMF sites to support a smooth transition to PYLARIFY TruVu, including providing guidance on ordering, handling, and clinical use.
• The company plans to pursue reimbursement for PYLARIFY TruVu from CMS, including seeking three years of Transitional Pass-Through Payment Status (TPT Status).
• The timing of the PNT2003 launch will consider final FDA approval, the expiration of the 30-month Hatch-Waxman stay, disposition of related legal proceedings, and manufacturing and commercial strategy.
• The company is streamlining operations to focus mainly on its radiodiagnostic business and pursue value-maximizing alternatives for its radiotherapeutic assets.

Industry Context

StockSavvy.ai notes that Lantheus Holdings' Q1 2026 results reflect a dynamic radiopharmaceutical market. The company's strategic shift towards PET radiodiagnostics and the continued integration of recent acquisitions (Evergreen and Lantheus Biosciences) align with industry trends emphasizing precision medicine and targeted therapies. The competitive landscape for PSMA PET imaging agents remains intense, with ongoing developments in tracer technology and reimbursement policies influencing market share.

Comparison to Industry Standards

• Lantheus Holdings' revenue growth of 1.2% in Q1 2026 is moderate compared to the high-growth rates often seen in the specialized radiopharmaceutical sector, where companies like GE HealthCare and Novartis (through its AAA subsidiaries) are also active.
• The company's focus on PET imaging aligns with industry trends, as PET scans are increasingly adopted for diagnosis and treatment monitoring, particularly in oncology and neurology.
• The company's gross profit margin of approximately 61% is within the typical range for pharmaceutical and biotechnology companies, though it has seen a slight decrease due to increased costs.
• The significant increase in net income is largely attributable to a one-time gain from the sale of a business segment, which is not indicative of ongoing operational performance.
• The company's R&D investment as a percentage of revenue (approximately 10.3%) is consistent with industry benchmarks for companies investing in pipeline development and innovation.

Legal Proceedings

• Patent infringement lawsuit filed by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA (Novartis entities) regarding PNT2003; awaiting court decision.
• Putative securities class action lawsuit filed by an alleged stockholder (Margolis v. Lantheus Holdings, Inc., et al.) and a related action (Indiana Pub. Ret. Sys. v. Lantheus Holdings, Inc., et al.), now consolidated, alleging materially false or misleading statements.
• Shareholder derivative action filed by an alleged stockholder (Lelchuk v. Heino et al.) alleging breaches of fiduciary duties and other claims, stayed pending certain events.

Stakeholder Impact

• Shareholders: The gain on sale of the SPECT business positively impacts net income. However, increased operating expenses and competition for key products may affect future profitability.
• Employees: Increased R&D and sales & marketing expenses suggest continued investment in growth and product development, potentially leading to future opportunities. Stock-based compensation remains a significant expense.
• Customers: The transition to PYLARIFY TruVu may offer improved manufacturing and distribution, but requires careful management to ensure continuity of care. Reimbursement changes could impact purchasing decisions.
• Suppliers: The company relies on third-party suppliers for imaging agents, with agreements like the JHS MSA for DEFINITY extending through 2027.

Next Steps

• Complete technology transfer for PYLARIFY TruVu across the PMF network and obtain FDA approval for each PMF site.
• Pursue reimbursement for PYLARIFY TruVu from CMS, including seeking three years of TPT Status.
• Transition customers from PYLARIFY to PYLARIFY TruVu, expected to begin in Q4 2026.
• Obtain final FDA approval for PNT2003 and manage legal proceedings.
• Initiate registrational program for LNTH-2401 in patients with prostate cancer.
• Continue to monitor and manage market dynamics for PYLARIFY and other products.
• Integrate acquisitions of Lantheus Biosciences and Evergreen Theragnostics, Inc.

Key Dates

Recommendation

Lantheus Holdings demonstrates consistent revenue growth and strategic acquisitions, but faces increasing competition and rising operating costs. The significant gain from the SPECT sale masks operational pressures. While the pipeline is promising, the delays in regulatory approvals and the complexities of product transitions warrant a cautious 'hold' stance until clearer execution on future growth drivers is demonstrated.

Keywords

Lantheus Holdings, 10-Q, Quarterly Report, Radiopharmaceuticals, PET imaging, PYLARIFY, Neuraceq, DEFINITY, Oncology, Neurology, Cardiology, SPECT business sale, Acquisitions, Financial Results